Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Mouth Neoplasms 1

Interventions

Cisplatin 281pembrolizumab 234Radiotherapy 171Cetuximab 169Carboplatin 123Docetaxel 110Paclitaxel 96Fluorouracil 95Nivolumab 88Radiotherapy, Intensity-Modulated 80Magnetic Resonance Spectroscopy 39durvalumab 36Radiation 33Surgical Procedures, Operative 32Drug Therapy 32Biopsy 28Radiosurgery 25Erlotinib Hydrochloride 25Albumin-Bound Paclitaxel 24130-nm albumin-bound paclitaxel 24Taxes 23Specimen Handling 22Platinum 22Immunohistochemistry 21tislelizumab 201,2-diaminocyclohexaneplatinum II citrate 20Cyclophosphamide 19Chemoradiotherapy 19Capecitabine 19tremelimumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × tozuleristide × Head & Neck × Clear all
NCT05316688 2026-02-25

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

University of Washington

Phase 1/2 Terminated
8 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡